Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors

OBJECTIVE: To evaluate the efficacy of ixekizumab (IXE), a monoclonal antibody selectively targeting interleukin-17A, in patients with inadequate response to one or two TNF inhibitors (TNFi). METHODS: A phase 3 study (SPIRIT-P2; NCT02349295) randomized patients with PsA with inadequate response or i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirkham, Bruce, Sesin, Carlos, Gellett, Amanda M., Sprabery, Aubrey T., Lin, Chen-Yen, Turkiewicz, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410000/
https://www.ncbi.nlm.nih.gov/pubmed/33479721
http://dx.doi.org/10.1093/rheumatology/keaa824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410000/
https://www.ncbi.nlm.nih.gov/pubmed/33479721
http://dx.doi.org/10.1093/rheumatology/keaa824

Ejemplares similares